Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H15NO.C4H4O4 |
Molecular Weight | 281.3044 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.C#CCO[C@H]1CN2CCC1CC2
InChI
InChIKey=SBCXBWBXWKVIFK-PBBCPHEYSA-N
InChI=1S/C10H15NO.C4H4O4/c1-2-7-12-10-8-11-5-3-9(10)4-6-11;5-3(6)1-2-4(7)8/h1,9-10H,3-8H2;1-2H,(H,5,6)(H,7,8)/b;2-1+/t10-;/m0./s1
Talsaclidine (WAL-2014) is a selective full agonist of M1 muscarinic receptor, having partial agonist activity on the M2 and M3 subtypes (with no in vivo consequences). The general receptor profile of talsaclidine demonstrates a nearly specific interaction with muscarinic receptors, having only weak binding affinity for alpha1- and nicotinic receptors. The drug is being tested in phase III of clinical trials for the treatment of Alzheimer's disease.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11392631 |
18.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10188789 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TALSACLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
730 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10188789 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
TALSACLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10188789 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TALSACLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4500 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10188789 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
TALSACLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11037112 |
TALSACLIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. | 2003 |
|
Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. | 2004 Jul 15 |
|
Zinc uptake is mediated by M1 muscarinic acetylcholine receptors in differentiated SK-SH-SY5Y cells. | 2006 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02248116
Talsaclidine is administered orally at a dose of 24 mg, three times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9272924
Isolated tracheal muscle from guinea-pigs was incubated with 1-3000 uM of talsaclidine to test the muscarinic receptor agonism.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2111051
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY | |||
|
C079885
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY | |||
|
C152500
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY | |||
|
6918244
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY | |||
|
147025-54-5
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY | |||
|
6A7C8SIH42
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY | |||
|
GG-45
Created by
admin on Fri Dec 15 15:47:58 GMT 2023 , Edited by admin on Fri Dec 15 15:47:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD